Quantum BioPharma Soars 19.33% on Celly Nutrition Product Launch

On March 28, 2025, Quantum BioPharma's stock rose to 19.33 in pre-market trading.

Quantum BioPharma's stock surged after its licensee, Celly Nutrition Corporation, released a new format of its alcohol detox product. This development has significantly boosted investor confidence in the company's growth prospects.

In addition to the product release, Quantum BioPharma's 2024 financial statements revealed strong improvements in cash flow, working capital, and operating efficiency. The company has also successfully removed material uncertainty, further stabilizing its financial position.

Quantum BioPharma retains a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzd™, the alcohol detox product. This strategic partnership is expected to drive future revenue growth for Quantum BioPharma.